Nuvilex, Inc.'s Cell-in-a-Box Treatment Called Magic Bullets of 21st Century by World Renowned Oncologist
May 05 2014 - 9:00AM
Marketwired
Nuvilex, Inc.'s Cell-in-a-Box Treatment Called Magic Bullets of
21st Century by World Renowned Oncologist
NEW YORK, NY--(Marketwired - May 5, 2014) - Nuvilex, Inc.
(OTCQB: NVLX) continued to awe investors last week with yet another
marquee name that has agreed to work with its pancreatic cancer
treatment of Cell-in-a-Box® combined with the anticancer drug
ifosfamide. As the company heads into late phase clinical trials,
it will do so with both a familiar name to the treatment and to the
field of oncology in Dr. Matthias Lohr of the famed Karolinska
Institute in Stockholm, Sweden.
Outside of Austrianova's Dr.'s Gunzburg and Salmons, there may
not be a bigger fan of this advanced pancreatic cancer treatment
than Dr. Lohr. After all, Dr. Lohr along with Dr.'s Gunzburg and
Salmons collaborated to write and publish an Abstract where they
called the treatment using encapsulated live-cells capable of
activating the anticancer drug ifosfamide into its cancer killing
form at the site of the tumor: "The Magic Bullets of the 21st
Century."
Today, we know that treatment as the Cell-in-a-Box® technology
combined with ifosfamide that Nuvilex will use to go head to head
with the "gold standard" for pancreatic cancer, Celegene's
Abraxane® plus gemcitabine.
While Nuvilex is a small international biotech firm, it is
attracting some of the biggest names in oncology, and some of the
greatest minds in pancreatic cancer. With Dr. Lohr agreeing to
continue his work with what is now Nuvilex's treatment, it marks
what should be seen as another strong endorsement that there is
something attractive about what the Cell-in-a-Box®/ifosfamide
combination can contribute to advanced pancreatic cancer.
Clearly the sharpest minds in the industry think Nuvilex's
treatment can move the needle on this deadly cancer, and having Dr.
Lohr, who was the Principal Investigator in the treatment's two
successful Phase 1/2 clinical trials, back "in the fold" is truly a
great "get" for Nuvilex and its executives.
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a
platform for corporate stories to unfold in the media with Reports,
Interviews and Articles. SMMG is compensated for Nuvilex articles,
reports, and interviews by a third party who reserves the right to
buy, sell or remain neutral on securities after the publication of
this article. SMMG has received total compensation of $81,695 for
content related to Nuvilex. Additionally, a principal at SMMG
currently owns 200,000 total shares of Nuvilex issued by the
company through a consulting agreement which has since ended for
work unrelated to content development. The shares have been held
for the requisite period under Rule 144 as of April 30, 2013, and
are eligible to be sold immediately. None of the Rule 144 eligible
shares have been sold; however, the principal reserves the right to
sell all or part of those shares in Nuvilex at any time without
further notice. For more information:
www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email Contact